Walleye Trading LLC bought a new stake in Verastem, Inc. (NASDAQ:VSTM – Get Rating) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 60,814 shares of the biopharmaceutical company’s stock, valued at approximately $71,000.
Other institutional investors also recently modified their holdings of the company. Wetherby Asset Management Inc. bought a new position in shares of Verastem in the first quarter valued at approximately $134,000. Hsbc Holdings PLC bought a new position in Verastem during the first quarter valued at $66,000. XTX Topco Ltd bought a new position in Verastem during the first quarter valued at $37,000. Mirabella Financial Services LLP bought a new position in Verastem during the first quarter valued at $36,000. Finally, Eaton Vance Management bought a new position in Verastem during the first quarter valued at $28,000. 58.55% of the stock is owned by institutional investors.
Verastem Trading Up 1.4 %
NASDAQ:VSTM opened at $0.41 on Monday. The company has a market cap of $85.70 million, a P/E ratio of -1.05 and a beta of 0.62. The stock’s fifty day moving average price is $0.61 and its two-hundred day moving average price is $0.99. Verastem, Inc. has a 1 year low of $0.29 and a 1 year high of $3.02. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.97 and a quick ratio of 4.97.
Analyst Upgrades and Downgrades
Verastem, Inc, a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK.
- Get a free copy of the StockNews.com research report on Verastem (VSTM)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.